[Transplacental carcinogenesis].
D015127:9,10-Dimethyl-1,2-benzanthracene; D000014:Abnormalities, Drug-Induced; D000230:Adenocarcinoma / Q000139:chemically induced; D000818:Animals; D002273:Carcinogens / Q000032:analysis / Q000378:metabolism; D006224:Cricetinae; D004054:Diethylstilbestrol / Q000009:adverse effects; D004622:Embryo, Mammalian; D005260:Female; D005865:Gestational Age; D006801:Humans; D008658:Inactivation, Metabolic; D008431:Maternal-Fetal Exchange; D051379:Mice; D009369:Neoplasms / Q000139:chemically induced*; D009374:Neoplasms, Experimental / Q000139:chemically induced; D009603:Nitroso Compounds / Q000096:biosynthesis; D009924:Organ Culture Techniques; D011247:Pregnancy; D051381:Rats; D013723:Teratogens / Q000032:analysis; D013792:Thalidomide / Q000009:adverse effects; D002583:Uterine Cervical Neoplasms / Q000139:chemically induced; D014625:Vaginal Neoplasms / Q000139:chemically induced
D002273:Carcinogens; D009603:Nitroso Compounds; D013723:Teratogens; D013792:Thalidomide; D015127:9,10-Dimethyl-1,2-benzanthracene; D004054:Diethylstilbestrol
Transplatsentarnyĭ kantserogenez.